Pfizer: FDA approves new lung cancer drug

(CercleFinance.com) - US regulators have approved Pfizer's third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of ALK-positive metastatic non-small cell lung cancer, the drugmaker said on Friday.


The US Food and Drug Administration had approved Lorbrena for patients with ALK-positive metastatic non-small cell lung cancer whose disease had progressed on crizotinib, another Pfizer drug, and at least one other ALK inhibitor.

This represents the third FDA approval Pfizer has received for an oncology treatment, including two lung cancer medicines, within two months, the company said.

Lorbrena is currently approved in Japan for the treatment of ALK fusion gene-positive unresectable advanced and/or recurrent non-small cell lung cancer.

Copyright (c) 2018 CercleFinance.com. All rights reserved.